Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Icahn School of Medicine at Mount Sinai
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Incyte Corporation
City of Hope Medical Center
Janssen Research & Development, LLC
UNC Lineberger Comprehensive Cancer Center
AstraZeneca
AstraZeneca
Hoffmann-La Roche
M.D. Anderson Cancer Center
Hoffmann-La Roche
M.D. Anderson Cancer Center
Bristol-Myers Squibb
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Hoffmann-La Roche
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Michigan Rogel Cancer Center
AstraZeneca
Novartis
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
UNC Lineberger Comprehensive Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)
University of Wisconsin, Madison
Hoffmann-La Roche
AstraZeneca
University of Michigan Rogel Cancer Center
Hoffmann-La Roche
BeOne Medicines
AstraZeneca
Wake Forest University Health Sciences